ACP
CLVS

Acuta Capital Partners’s Clovis Oncology, Inc. CLVS Stock Holding History

Acuta Capital Partners’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-30,000
Closed -$1.05M – 57
2015
Q4 		$1.05M Buy
+30,000
New +$1.93M 0.5% 41

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Acuta Capital Partners's CLVS Position: Q3 2017 in Review

Acuta Capital Partners sold out of Clovis Oncology, Inc. (CLVS) in Q3 2017, closing a stake of 20,000 shares — an estimated $1.59M sold.

Acuta Capital Partners first reported a position in CLVS in Q1 2017 and held it in 2 quarters. The position peaked at $2.57M in Q1 2017. 255 funds tracked by Wall St. Rank hold CLVS as of Q3 2017.

  • Acuta Capital Partners reported no remaining Clovis Oncology, Inc. position as of Q3 2017 after selling out during the quarter.
  • Acuta Capital Partners sold 20,000 Clovis Oncology, Inc. shares in Q3 2017, an estimated $1.59M.
  • Acuta Capital Partners first reported a position in Clovis Oncology, Inc. in Q1 2017 and held it in 2 quarters.
  • Acuta Capital Partners's Clovis Oncology, Inc. position peaked at $2.57M in Q1 2017.
  • 255 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2017.

Based on Acuta Capital Partners's 13F filing for Q3 2017, filed 14 Nov 2017.